Latest News

07/12/2021

Emergence Therapeutics raises €87 million Series A financing to advance Nectin-4 ADC

Series A round led by Pontifax and includes new and existing investors Lead product is a next-generation Nectin-4 ADC designed to increase efficacy and minimize toxicity Strategy is to become a dominant ADC developer   Duisburg, Germany, 7 December 2021. Emergence Therapeutics AG, a biopharmaceutical company developing novel antibody drug conjugates (ADC) for the treatment...

View Article >
05/10/2021

Emergence Therapeutics and Mablink Bioscience Enter into a Licensing Agreement to Develop Antibody Drug Conjugate as a potential cancer therapy

Emergence Therapeutics obtains the rights to develop a novel antibody-drug conjugate using Mablink Bioscience’s proprietary PSARlink™ drug-linker technology. Duisburg, Germany, and Lyon, France, 5 October 2021. Emergence Therapeutics AG, a European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat cancers with high unmet needs and Mablink Bioscience S.A.S. a biotechnology company developing...

View Article >
25/11/2020

Emergence Therapeutics Announces Bumped-up Follow-on Seed Round Financing

Financing enables company to embark on additional targets and expand ADC technology reach Duisburg, Germany – Marseille, France, 25 November 2020: Emergence Therapeutics AG, a European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat high need cancers, announces that is has closed a Bumped-up Follow-on Seed Round Financing from a syndicate of...

View Article >
10/03/2020

Emergence Therapeutics AG Announces Establishment of Scientific Advisory Board

Key Opinion Leaders bring many years of ADC development expertise to the company

Duisburg, Germany - Marseille, France, 10 March 2020: Emergence Therapeutics today announced that is has established its Scientific Advisory Board (SAB) to support the company in its goal to develop novel and innovative antibody-drug-conjugates (ADCs).

View Article >
22/01/2020

Emergence Therapeutics AG Announces Key Hirings to Senior Management Team

Substantial experience in cancer targets, ADC technology as well as corporate finances and law Duisburg, Germany – Marseille, France, 22 January 2020: Emergence Therapeutics announced today that is has hired Florence Lhospice as Chief Development Officer and Carsten Dehning as Chief Financial Officer and member of the Executive Board to complement its management team. Dr....

View Article >
22/11/2019

Emergence Therapeutics AG Announces Seed Round Financing; Enters into Nectin-4 and Key ADC Technology License Agreements

Lead program is a Nectin-4-targeting ADC with potential across a range of hard to treat cancers Duisburg, Germany – Marseille, France, 22 November 2019: Emergence Therapeutics announced today that is has entered into a definitive financing agreement with a syndicate of leading European life science investors. In this Seed Round, founding investor Kurma Partners was...

View Article >

Latest Events